{
  "note_id": "gold_t2dm_000",
  "scenario": "t2dm",
  "persona": "gold",
  "note_text": "**Clinical Note**\n\n**Patient Name:** Robert Chen  \n**Date of Birth:** [DOB]  \n**Visit Date:** [Date]  \n**Age:** 42 years  \n**Gender:** Male  \n**Occupation:** Software Engineer  \n**BMI:** 32.4  \n\n**Chief Complaint:**  \n\"Diabetes follow-up\"\n\n**History of Present Illness:**  \nRobert Chen is a 42-year-old male with a 3-year history of Type 2 Diabetes Mellitus. He is here for routine management. His last HbA1c, taken 3 months ago, was 8.2%. Despite adherence to Metformin 1000mg twice daily, his home glucose readings remain elevated, with fasting levels ranging from 160-220 mg/dL and postprandial levels from 180-250 mg/dL. He reports occasional gastrointestinal upset but tolerates the medication. He denies any episodes of hypoglycemia. The last eye exam 8 months ago showed no retinopathy. Today\u2019s foot exam revealed intact protective sensation but occasional tingling in the feet. He also reports occasional erectile dysfunction, potentially related to diabetes. He maintains a sedentary lifestyle, struggles with portion control, and consumes soda daily.  \n\n**Review of Systems:**  \n- **Constitutional:** No weight loss.  \n- **Eyes:** No visual changes.  \n- **Cardiovascular:** No chest pain.  \n- **Respiratory:** No shortness of breath.  \n- **Gastrointestinal:** Occasional GI upset from Metformin.  \n- **Genitourinary:** Occasional erectile dysfunction.  \n- **Endocrine:** No polyuria, polydipsia.  \n- **Neurological:** Reports occasional tingling in feet.  \n- **Dermatological:** No skin changes or wounds.\n\n**Past Medical History:**  \n- Type 2 Diabetes Mellitus  \n- Hypertension (controlled on Lisinopril)  \n- Hyperlipidemia  \n\n**Medications:**  \n- Metformin 1000mg twice daily  \n- Lisinopril 20mg daily  \n- Atorvastatin 20mg daily  \n\n**Allergies:**  \nNo known drug allergies.\n\n**Social History:**  \nRobert works as a software engineer, implying a sedentary lifestyle. He performs minimal physical exercise and struggles with dietary habits, particularly with portion control and soda consumption.\n\n**Physical Examination:**  \n- **Vital Signs:** BP 128/78 mmHg, HR 78, Weight 185 lbs, BMI 32.4, Temperature 98.6\u00b0F  \n- **General:** Alert, obese, pleasant demeanor.  \n- **Cardiovascular:** Regular rate and rhythm, no murmurs, peripheral pulses 2+ dorsalis pedis and posterior tibial bilaterally.  \n- **Respiratory:** Clear to auscultation bilaterally.  \n- **Extremities:** Monofilament test intact, skin intact without wounds or calluses, no edema, pedal pulses palpable.  \n- **Feet:** No deformities, nails trimmed, no fungal infection.\n\n**Assessment and Plan:**  \n1. **Type 2 Diabetes Mellitus, uncontrolled (ICD-10: E11.65):**  \n   - Add Semaglutide 0.25mg subcutaneous weekly, increase to 0.5mg after 4 weeks.  \n   - Continue Metformin 1000mg twice daily.  \n   - Order HbA1c in 3 months.  \n   - Referral to diabetes educator for nutrition counseling.  \n   - Patient education on glucose targets and lifestyle modifications.\n\n2. **Obesity (ICD-10: E66.9):**  \n   - Lifestyle counseling: Eliminate sugar-sweetened beverages, portion control, increase physical activity to 150 min/week.  \n   - Weight loss goal: 5-10% body weight over 6 months.\n\n3. **Essential hypertension, controlled (ICD-10: I10):**  \n   - Continue Lisinopril 20mg daily.\n\n4. **Hyperlipidemia (ICD-10: E78.5):**  \n   - Continue Atorvastatin 20mg daily.\n\n5. **Complications: Neuropathy symptoms:**  \n   - Monitor symptoms, address glucose control.\n\n6. **Preventive Care:**  \n   - Referral to ophthalmology for annual dilated eye exam.  \n   - Order annual kidney function tests.  \n   - Ensure flu vaccine, check pneumococcal status.\n\n7. **Erectile Dysfunction:**  \n   - Discussed relationship to diabetes; consider PDE5 inhibitors if persistent.\n\n**Time Spent:** 25 minutes with extensive medication counseling and lifestyle education.\n\n**Billing Level:** 99214 (Established patient, moderate to high complexity due to uncontrolled chronic disease).\n\n**Medical Decision Making:**  \nComprehensive assessment of glycemic control with HbA1c at 8.2%. Decided to add GLP-1 agonist for its dual benefits in glucose control and weight loss, given the elevated cardiovascular risk profile. Explored lifestyle barriers and provided detailed guidance on lifestyle modifications. Placed a referral to ophthalmology for overdue eye examination.",
  "demographics": {
    "age": 42,
    "gender": "M",
    "occupation": "software engineer",
    "name": "Robert Chen"
  },
  "generated_at": "2026-02-14T01:54:58.253251",
  "ground_truth_scores": {
    "completeness": 92,
    "accuracy": 95,
    "compliance": 90,
    "risk": 93,
    "clarity": 94
  }
}